Velgia® is a revolutionary solution in the fight against obesity

Velgia® It is aimed at overweight and obese patients. The drug contains specially selected concentrations and increased dosages of the active substance, which increases its therapeutic effectiveness. Velgia significantly reduces weight and helps to correct metabolic disorders that underlie the formation of a number of cardiovascular and oncological diseases, which are the main causes of death in our country.

According to a study published in The Lancet medical journal, the number of obese people in the world has exceeded 1 billion by 2022. According to official statistics from the Ministry of Health, more than 44 million obese people have been registered in Russia and their number continues to grow.

Excess weight is the cause of the development of many pathological conditions, such as type 2 diabetes mellitus and cardiovascular diseases (strokes, heart attacks). Obesity reduces life expectancy by an average of 3-10 years, depending on the severity, and has become a real threat to the health of the nation.

The event was attended by the country's leading experts in the field of endocrinology. The most pressing issues related to the problem of obesity were raised and a solution was presented: the revolutionary drug Velgia®. The single leitmotif of the meeting was the discussion of joining efforts to manage the nation's metabolic health.

Ekaterina Anatolyevna Troshina, Corresponding Member of the Russian Academy of Sciences, Professor, MD noted: "Obesity is a serious socially significant problem leading to a decrease in the quality of life, disability of the population and a significant increase in the costs of the healthcare system. The prevalence of obesity is growing at a gigantic pace. In our country alone, more than 44 million people are obese and need affordable, effective and safe therapy. The medical community welcomes the new achievements of Promomed aimed at restoring metabolic health. The new drug is an example of providing our patients with the most modern and currently available therapy. It is worth noting that this is a big step in solving this important medical and social problem."

Alexander Ametov, MD, Professor, Head of the Department of Endocrinology of the Russian Ministry of Health, UNESCO Network Chair on the topic "Bioethics of Diabetes Mellitus":

"Our task is to popularize knowledge about such a serious disease as obesity. A person may not even know that they are sick, and our goal is to increase people's life expectancy by raising their awareness. The uniqueness of Velgia®, in addition to significant results in weight loss, lies in the fact that it helps to correct metabolic disorders that underlie the formation of a number of cardiovascular and oncological diseases - the main causes of death in our country - and is a kind of "survival molecule". This is rightfully a disease-modifying therapy."

Tatiana Nikolaevna Markova, Professor of the Department of Endocrinology and Diabetology at the Russian University of Medicine, MD, emphasized:

"Velgia^® developed by Promomed specifically for the treatment of obesity, it contains specially selected concentrations and increased dosages of the active substance, which increases its therapeutic effectiveness. A convenient pen, simple and affordable therapy will allow you to achieve your goals of weight loss, maintaining health and beauty."

Kira Yakovlevna Zaslavskaya, Director of New Products, member of the Board of Directors of Promomed Group, focused on the specifics of drug synthesis and control over all stages of its production:

"The technology developed by the Company for the production of Velgia® from the chemical synthesis of the substance to the finished, easy-to-use dosage form, it allows to achieve the highest quality of the product and guarantees uninterrupted provision of patients with sought-after therapy. This is especially important given the chronic nature of the disease. We, like no one else, understand the need for continuous treatment and the large-scale prevalence of obesity, which has the character of a non-communicable pandemic that is rapidly gaining momentum."

Among the speakers of the event:

-Ekaterina Anatolyevna Troshina, Corresponding Member of the Russian Academy of Sciences, Professor, MD.
-Alexander Sergeyevich Ametov, Professor, MD, Head of the Department of Endocrinology, GBOU DPO RMANPO of the Ministry of Health of the Russian Federation
-Tatiana Nikolaevna Markova, Professor of the Department of Endocrinology and Diabetology at the Russian University of Medicine, MD, Head of the Department of Endocrinology at the Moscow Department of Public Health "GCB No. 52"
-Kira Yakovlevna Zaslavskaya, Director of New Products, Member of the Board of Directors of Promomed Group

The moderator was Evelina Zakamskaya, TV presenter, Rossiya 24 TV channel; editor-in-chief, Doctor TV channel

The event was actively attended and questions were answered by the heads of Promomed company: Peter Alexandrovich Bely, Chairman of the Board of Directors of Promomed Group, Alexander Efremov, CEO of Promomed PJSC, member of the Board of Directors of Promomed Group, Ilya Nikolaevich Bardin-Denisov, CEO of Promomed DM LLC, as well as journalists from federal and specialized media, actors, including Kristina Babushkina, influencers and representatives of the banking sector.